

Clinical data on RA blood test, 2/15

February 2014—Crescendo Bioscience, a wholly owned subsidiary of Myriad Genetics, presented data that showed Vectra DA is a better predictor of radiographic progression over two years than other tests used to assess risk of joint damage in rheumatoid arthritis.

The study included 143 patients with RA who had received a stable treatment and were enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study registry in the U.S. Patients were evaluated at their initial visit in the BRASS registry for the Vectra DA score and conventional measures of disease activity, including C-reactive protein, Disease Activity Score 28-CRP, Clinical Disease Activity Index, Simple Disease Activity Index, and Routine Assessment of Patient Index Data 3, and provided x-rays of hands and wrists at approximately the initial visit and two years later. These data were used to assess the relationship between disease activity and the amount of subsequent new joint damage seen on x-rays.

The results showed that Vectra DA was the best independent predictor of disease progression over two years when compared with standard measures based on the exam or patient reported outcome. Among patients with a low CRP at baseline, defined as

[Crescendo Bioscience](#), 650-351-1354